What is the prognosis for acute myeloid M2a leukemia???

The prognosis of leukemia is not bad, and you should be mentally prepared. But hopefully you have faith that miracles will happen.

Let's go to a regular hospital, I mean a regular big hospital, not a hospital that fools people, ask more clearly.

I don't know how your first course of treatment was relieved, and whether it was ** halfway.

After ten times of chemotherapy, I should have persevered for half of it, and I should have a certain understanding of the disease for so long, I know two m2 chemotherapy for two years, and the recovery is very good, and you should stick to it.

Decrease in red blood cells and platelets can lead to: anemia, bleeding tendency.

A decrease in normal white blood cells can lead to a predisposition to infection.

Sick leukocyte infiltration can cause: bone and joint pain. Headache, nausea, vomiting, proptosis, diplopia, blindness, etc. Each patient may present with different symptoms depending on the site of the invasion, and all of these symptoms may occur in patients with a long course of disease.

Hello, this is the case, the symptom: bleeding. It is more common with petechiae, ecchymosis, nosebleeds, and bleeding gums.

Visual impairment caused by fundus and retinal hemorrhage is also common, and often occurs at the same time as bleeding in other parts, which can be a precursor to intracranial hemorrhage. Intracranial hemorrhage is accompanied by headache, vomiting, asymmetrical pupils, and even death from coma. can rely on "Qi Feng's Acute Carcinogenic Heart" to alleviate.

The symptoms of each patient are different, but generally there will be weakness, dizziness, palpitations, palpitations and other phenomena, and the blood routine examination is low.

It is not certain that some will survive for a long time, and some will not be there for three to six months, mainly depending on the situation. If it is this kind of spirit of expectation and hard work in life, it will definitely get better.

Now the best way to get leukemia is a bone marrow transplant, which requires about 200,000 yuan!

Acute non-gonorrhea leukemia is currently divided into M0 and M7, with a total of 8 models. Among them, M3 type (promyelocytic leukemia) has been expected to be all ** under the guidance of Chinese doctors! M2 with T(8,21), M4EO with T(16,16), M3 with T(15,17), and all normal karyotypes were high**.

Other acute non-lyric chemotherapy** rates are less than 30%.

Acute leukemia acute non-lymphocytic leukemia M2 type, also known as acute non-lymphocytic leukemia partially differentiated type, it is divided into two types, namely M2A and M2B type, generally after the standard ** can achieve a state of complete remission, however, acute leukemia even complete remission ** rate is very high. At present, the best method is to perform allogeneic hematopoietic stem cell transplantation after complete remission, and the 5-year survival rate of acute non-lymphoblastic leukemia M2B is generally 60%, that is, the 5-year survival rate of patients after complete remission is not more than 60%. Please refer to it.

Hello! At present, it is in a state of complete remission, generally speaking, each consolidation and intensification ** has achieved significant myelosuppression, and 8 times of chemotherapy after remission should be sufficient, and discontinuation can be considered; If there is a condition for bone marrow transplantation, the empty carrier can control the minimal residual disease to the greatest extent, laying the foundation for long-term disease-free survival and even **; If transplantation cannot be carried out, it is recommended to actively nourish qi and nourish yin, clear and treat residual poisons, and the purpose of obvious prevention and treatment can be obtained! If it is convenient, it is recommended to ask your relatives, friends and classmates in Guangzhou to bring the diagnosis and treatment materials and tell the condition, you can give a prescription in the outpatient clinic and treat it in a different place, hoping to get good results, I wish you an early **!

Dr. Li Da, Director of the Department of Hematology of Guangdong Provincial Hospital of Traditional Chinese Medicine, wishes an early **!

Li Da, Guangdong Provincial Hospital of Traditional Chinese Medicine.

Hello, acute leukemia is a malignant tumor disease of the blood system, there are many types of acute leukemia, among which myeloid type M3 is currently considered a disease that can be regarded as ** due to targeted drugs, M2A is a more common type in clinical practice, but the ** effect of this kind of leukemia is not very good, and the long-term prognosis is not ideal, the main ** is long-term chemotherapy, but not completely**. If possible, bone marrow transplantation can be considered, which is currently the only way to ** leukemia, but the risk is very large. Hello, although leukemia is a malignant disease of hematopoietic tissues, the development of medical technology has made leukemia a treatable disease.

Through active chemotherapy, radiotherapy, bone marrow or peripheral blood stem cell transplantation, biological response modifiers and traditional Chinese medicine applications, more than half of the patients have been able to prolong survival. A small number of patients are cured.

The median survival after chemotherapy for chronic myeloid leukemia is about 39 to 47 months, the 5-year survival rate is 25% to 35%, the 8-year survival rate is 8% to 17%, and the individual can survive for 10 to 20 years.

The main prognostic factors affecting chronic myeloid leukemia are: prognostic risk score at initial diagnosis; **Manner; Evolution of the course of the disease. In recent years, allogeneic hematopoietic stem cell transplantation ALLO-SCT and imatinib mesylate** chronic myeloid leukemia have changed the prognosis and survival of chronic myeloid leukemia.

Overall, IFN-ara-c is superior to HU and imatinib mesylate is superior to ifn-ara-c for patients with chronic myeloid leukemia.

Allo-SCT is a well-established method suitable for long-term complete molecular biological remission and a rate of about 50% in transplant patients. Imatinib mesylate and allo-SCT are currently the preferred modalities.